Skip to contentpdufa.bio

MYQORZO (aficamten): FDA NDA 219083

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 219083 is the FDA application for MYQORZO (aficamten). The FDA's Orange Book lists the applicant of record as CYTOKINETICS INC and the first approval on it as Dec 19, 2025. Code names used in development: CK-274, CK-3773274. Owner today: Cytokinetics, Incorporated (Nasdaq: CYTK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 219083 · Orange Book NDA 219083

Names for this drug

Brand name (FDA)MYQORZO
Orange Book trade name: MYQORZO
Active ingredient (FDA)AFICAMTEN
Code nameCK-274
Source: Cytokinetics 10-K, Feb 25, 2022
“aficamten (also known as CK-274)”
Code nameCK-3773274
Source: Cytokinetics 10-K, Feb 25, 2022
“aficamten (also known asCK-3773274 or CK-274), a novel cardiac myosin inhibitor”

Who holds the application

FDA applicant of recordCYTOKINETICS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayCytokinetics, Incorporated (CYTK)
Source: Cytokinetics press release, Dec 19, 2025
“Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved”

Products on NDA 219083 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001MYQORZOTABLET;ORAL5MGDec 19, 2025
002MYQORZOTABLET;ORAL10MGDec 19, 2025
003MYQORZOTABLET;ORAL15MGDec 19, 2025
004MYQORZOTABLET;ORAL20MGDec 19, 2025

FDA decisions we track for this drug

Aficamten - (MAPLE-HCM)CYTK · Decided

Drug page: /drug/myqorzo · /drug/aficamten

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.